Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed question first answered answering member label
tabling member	label

Search

1149774

	registered interest
	date	14/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bevacizumab
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether Avastin has approval from the European Medicines Authority to be used to treat cancer.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL67
	answer	answer is ministerial correction date of answer 25/10/2019 answer text <p>Avastin has approval from the European Medicines Agency to be used to treat cancer in combination with specific chemotherapies in the advanced stages of several cancers. They are:</p><p>- Metastatic colorectal cancer;</p><p>- Metastatic breast cancer;</p><p>- Certain types of unresectable advanced, metastatic or recurrent lung cancer;</p><p>- Advanced or metastatic renal cell cancer;</p><p>- Advanced or recurrent or resistant ovarian/fallopian tube cancer; and</p><p>- Persistent or recurrent or metastatic cervical cancer.</p><p>Full details of the indications that Avastin is licensed for can be found in the European public assessment report for Avastin. It explains how the Agency assessed the medicine to recommend its authorisation and its conditions of use and is publicly available on their website.</p> answering member printed Baroness Blackwood of North Oxford question first answered 25/10/2019 12:00:04 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

1149777

	registered interest
	date	14/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Transplant Surgery
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether liver and bowel transplantation is currently approved by the National Institute for Health and Care Excellence for cancer patients; and if not, whether there are any clinical trials that have reached Phase 3.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL70
	answer	answer is ministerial correction date of answer 25/10/2019 answer text <p>The National Institute for Health and Care Excellence has not produced any guidance relating to combined liver and bowel transplants for cancer patients.</p><p>The Department funds research mainly through the National Institute for Health Research (NIHR). The usual practice of the NIHR and other research funders is not to ring-fence funds for expenditure on particular topics. The NIHR welcomes funding applications for research into any aspect of human health, including liver and bowel transplantation.</p><p>There has been one relevant clinical trial that reached Phase 3:</p><p>Study title: In open, prospective, single arm study investigating efficacy and safety of human hepatitis B immunoglobulin Zutectra in liver transplanted patients - the ZEUS Study.</p><p>Date: 22 November 2012 – 10 April 2014</p> answering member printed Baroness Blackwood of North Oxford question first answered 25/10/2019 11:56:33 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

1149775

	registered interest
	date	14/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bevacizumab
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether there are (1) current applications, or (2) pending requests, for the use of Avastin following Phase 3 clinical trials.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL68
	answer	answer is ministerial correction date of answer 25/10/2019 answer text <p>To extend the indication of Avastin, the Marketing Authorisation Holder (Roche Registration GmbH) would need to submit the results of relevant clinical trials and other information to the European Medicines Agency (EMA) to demonstrate acceptable safety and efficacy and a positive balance of benefit to risk. At present, as Avastin has a European Community Marketing Authorisation, a national submission to the Medicines and Healthcare products Regulatory Agency to extend the indication is not possible.</p><p>There has not been any recent positive opinion from the EMA for a new indication of Avastin to be submitted to the European Commission and the EMA has not published any pending extension of indication applications.</p> answering member printed Baroness Blackwood of North Oxford question first answered 25/10/2019 12:11:29 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

1149773

	registered interest
	date	14/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bevacizumab
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government why Avastin is not routinely made available on the NHS for certain groups of cancer patients.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL66
	answer	answer is ministerial correction date of answer 25/10/2019 answer text <p>Most new medicines are assessed by the National Institute for Health and Care Excellence (NICE) which makes recommendations for the National Health Service on whether they represent a clinically and cost effective use of NHS resources. Since 2016, NICE makes recommendations for the NHS on all new licensed cancer medicines through its technology appraisal programme. NHS commissioners are legally required to fund treatments recommended in NICE technology appraisal guidance.</p><p>NICE has appraised Avastin (bevacizumab) for use in the treatment of a number of different types of cancer and has unfortunately not been able to recommend it as a clinically and cost effective use of NHS resources for any type of cancer at the price offered by the drug company. Avastin is not therefore routinely funded by the NHS for any licensed indication.</p><p>Avastin is funded as an off-label treatment for some types of cancer through the Cancer Drugs Fund.</p> answering member printed Baroness Blackwood of North Oxford question first answered 25/10/2019 11:56:13 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

1149776

	registered interest
	date	14/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bevacizumab
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, if Avastin is approved for safe use, whether it could be privately purchased for use by a patient being treated on the NHS.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL69
	answer	answer is ministerial correction date of answer 28/10/2019 answer text <p>For patients receiving private and National Health Service care for the same condition, NHS and private treatment can be supervised by one healthcare team. However, patients cannot choose to mix different parts of the same treatment between NHS and private care.</p><p>For example, a patient cannot have a cataract operation on the NHS and pay privately for special lens implants that are normally only available as part of private care.</p><p>Instead, a patient either has both the operation on the NHS and standard NHS lens implants or pay for both the operation and implants privately.</p> answering member printed Baroness Blackwood of North Oxford question first answered 28/10/2019 12:58:25 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough